Protara Therapeutics (TARA) Change in Accured Expenses (2013 - 2026)

Protara Therapeutics (TARA) has reported Change in Accured Expenses for 14 consecutive years, with -$2.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 39.14% year-over-year to -$2.6 million; the TTM figure through Mar 2026 stood at $89000.0 (up 888.89% YoY), while the FY2025 annual figure was $821000.0, down 69.32% from the prior year.
• Change in Accured Expenses declined to -$2.6 million in Q1 2026 per TARA's latest filing, from $2.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.0 million in Q4 2025 and bottomed at -$2.6 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$55117.6 across 5 years, with a median of $140000.0 in 2024.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 1898.08% — and 2025, when it surged 1360.0%.
• Protara Therapeutics' Change in Accured Expenses stood at -$1.2 million in 2022, then surged by 114.85% to $177000.0 in 2023, then decreased by 20.9% to $140000.0 in 2024, then soared by 1360.0% to $2.0 million in 2025, then sank by 227.3% to -$2.6 million in 2026.
• Business Quant data shows TARA's Change in Accured Expenses at -$2.6 million in Q1 2026, $2.0 million in Q4 2025, and $922000.0 in Q3 2025.